Editing human hematopoietic stem cells: advances and challenges
Genome editing of hematopoietic stem and progenitor cells is being developed for the treatment of several inherited disorders of the hematopoietic system. The adaptation of CRISPR-Cas9-based technologies to make precise changes to the genome, and developments in altering the specificity and efficien...
Gespeichert in:
| Veröffentlicht in: | Cytotherapy (Oxford, England) England), 2023-03, Vol.25 (3), p.261-269 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 269 |
|---|---|
| container_issue | 3 |
| container_start_page | 261 |
| container_title | Cytotherapy (Oxford, England) |
| container_volume | 25 |
| creator | Bhoopalan, Senthil Velan Yen, Jonathan S. Levine, Rachel M. Sharma, Akshay |
| description | Genome editing of hematopoietic stem and progenitor cells is being developed for the treatment of several inherited disorders of the hematopoietic system. The adaptation of CRISPR-Cas9-based technologies to make precise changes to the genome, and developments in altering the specificity and efficiency, and improving the delivery of nucleases to target cells have led to several breakthroughs. Many clinical trials are ongoing, and several pre-clinical models have been reported that would allow these genetic therapies to one day offer a potential cure to patients with diseases where limited options currently exist. However, there remain several challenges with respect to establishing safety, expanding accessibility and improving the manufacturing processes of these therapeutic products. This review focuses on some of the recent advances in the field of genome editing of hematopoietic stem and progenitor cells and illustrates the ongoing challenges. |
| doi_str_mv | 10.1016/j.jcyt.2022.08.003 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2716087870</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1465324922007496</els_id><sourcerecordid>2716087870</sourcerecordid><originalsourceid>FETCH-LOGICAL-c400t-d8dc3e5245ab3d12ef13c01cc184fc8591f327a97d09988cf84432ba3bc880b63</originalsourceid><addsrcrecordid>eNp9kMtOwzAQRS0EolD4ARYoSzYJYzsPByEhVJWHVIkNrC3HnrSO8iixU6l_T6IWlqxmFudezRxCbihEFGh6X0WV3vuIAWMRiAiAn5ALGmdZyJI0PZ32NAk5i_MZuXSuAmAgRHJOZjyljDMeX5CnpbHetutgMzSqDTbYKN9tO4ve6sB5bAKNde0eAmV2qtXoAtWaQG9UXWO7RndFzkpVO7w-zjn5ell-Lt7C1cfr--J5FeoYwIdGGM0xYXGiCm4ow5JyDVRrKuJSiySnJWeZyjMDeS6ELkUcc1YoXmghoEj5nNwderd99z2g87KxbjpNtdgNTrKMpiAykcGIsgOq-865Hku57W2j-r2kICdxspKTODmJkyDkKG4M3R77h6JB8xf5NTUCjwcAxy93FnvptMXRiLE9ai9NZ__r_wGfgX5_</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2716087870</pqid></control><display><type>article</type><title>Editing human hematopoietic stem cells: advances and challenges</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Bhoopalan, Senthil Velan ; Yen, Jonathan S. ; Levine, Rachel M. ; Sharma, Akshay</creator><creatorcontrib>Bhoopalan, Senthil Velan ; Yen, Jonathan S. ; Levine, Rachel M. ; Sharma, Akshay</creatorcontrib><description>Genome editing of hematopoietic stem and progenitor cells is being developed for the treatment of several inherited disorders of the hematopoietic system. The adaptation of CRISPR-Cas9-based technologies to make precise changes to the genome, and developments in altering the specificity and efficiency, and improving the delivery of nucleases to target cells have led to several breakthroughs. Many clinical trials are ongoing, and several pre-clinical models have been reported that would allow these genetic therapies to one day offer a potential cure to patients with diseases where limited options currently exist. However, there remain several challenges with respect to establishing safety, expanding accessibility and improving the manufacturing processes of these therapeutic products. This review focuses on some of the recent advances in the field of genome editing of hematopoietic stem and progenitor cells and illustrates the ongoing challenges.</description><identifier>ISSN: 1465-3249</identifier><identifier>EISSN: 1477-2566</identifier><identifier>DOI: 10.1016/j.jcyt.2022.08.003</identifier><identifier>PMID: 36123234</identifier><language>eng</language><publisher>England: Elsevier Inc</publisher><subject>CRISPR-Cas Systems - genetics ; CRISPR-Cas9 ; Gene Editing - methods ; Genetic Therapy - methods ; Hematopoietic Stem Cells ; Humans ; severe congenital neutropenia ; sickle cell disease</subject><ispartof>Cytotherapy (Oxford, England), 2023-03, Vol.25 (3), p.261-269</ispartof><rights>2022 International Society for Cell & Gene Therapy</rights><rights>Copyright © 2022 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c400t-d8dc3e5245ab3d12ef13c01cc184fc8591f327a97d09988cf84432ba3bc880b63</citedby><cites>FETCH-LOGICAL-c400t-d8dc3e5245ab3d12ef13c01cc184fc8591f327a97d09988cf84432ba3bc880b63</cites><orcidid>0000-0002-9432-9450 ; 0000-0002-3684-2950 ; 0000-0003-3281-2081</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36123234$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bhoopalan, Senthil Velan</creatorcontrib><creatorcontrib>Yen, Jonathan S.</creatorcontrib><creatorcontrib>Levine, Rachel M.</creatorcontrib><creatorcontrib>Sharma, Akshay</creatorcontrib><title>Editing human hematopoietic stem cells: advances and challenges</title><title>Cytotherapy (Oxford, England)</title><addtitle>Cytotherapy</addtitle><description>Genome editing of hematopoietic stem and progenitor cells is being developed for the treatment of several inherited disorders of the hematopoietic system. The adaptation of CRISPR-Cas9-based technologies to make precise changes to the genome, and developments in altering the specificity and efficiency, and improving the delivery of nucleases to target cells have led to several breakthroughs. Many clinical trials are ongoing, and several pre-clinical models have been reported that would allow these genetic therapies to one day offer a potential cure to patients with diseases where limited options currently exist. However, there remain several challenges with respect to establishing safety, expanding accessibility and improving the manufacturing processes of these therapeutic products. This review focuses on some of the recent advances in the field of genome editing of hematopoietic stem and progenitor cells and illustrates the ongoing challenges.</description><subject>CRISPR-Cas Systems - genetics</subject><subject>CRISPR-Cas9</subject><subject>Gene Editing - methods</subject><subject>Genetic Therapy - methods</subject><subject>Hematopoietic Stem Cells</subject><subject>Humans</subject><subject>severe congenital neutropenia</subject><subject>sickle cell disease</subject><issn>1465-3249</issn><issn>1477-2566</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtOwzAQRS0EolD4ARYoSzYJYzsPByEhVJWHVIkNrC3HnrSO8iixU6l_T6IWlqxmFudezRxCbihEFGh6X0WV3vuIAWMRiAiAn5ALGmdZyJI0PZ32NAk5i_MZuXSuAmAgRHJOZjyljDMeX5CnpbHetutgMzSqDTbYKN9tO4ve6sB5bAKNde0eAmV2qtXoAtWaQG9UXWO7RndFzkpVO7w-zjn5ell-Lt7C1cfr--J5FeoYwIdGGM0xYXGiCm4ow5JyDVRrKuJSiySnJWeZyjMDeS6ELkUcc1YoXmghoEj5nNwderd99z2g87KxbjpNtdgNTrKMpiAykcGIsgOq-865Hku57W2j-r2kICdxspKTODmJkyDkKG4M3R77h6JB8xf5NTUCjwcAxy93FnvptMXRiLE9ai9NZ__r_wGfgX5_</recordid><startdate>202303</startdate><enddate>202303</enddate><creator>Bhoopalan, Senthil Velan</creator><creator>Yen, Jonathan S.</creator><creator>Levine, Rachel M.</creator><creator>Sharma, Akshay</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9432-9450</orcidid><orcidid>https://orcid.org/0000-0002-3684-2950</orcidid><orcidid>https://orcid.org/0000-0003-3281-2081</orcidid></search><sort><creationdate>202303</creationdate><title>Editing human hematopoietic stem cells: advances and challenges</title><author>Bhoopalan, Senthil Velan ; Yen, Jonathan S. ; Levine, Rachel M. ; Sharma, Akshay</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c400t-d8dc3e5245ab3d12ef13c01cc184fc8591f327a97d09988cf84432ba3bc880b63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>CRISPR-Cas Systems - genetics</topic><topic>CRISPR-Cas9</topic><topic>Gene Editing - methods</topic><topic>Genetic Therapy - methods</topic><topic>Hematopoietic Stem Cells</topic><topic>Humans</topic><topic>severe congenital neutropenia</topic><topic>sickle cell disease</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bhoopalan, Senthil Velan</creatorcontrib><creatorcontrib>Yen, Jonathan S.</creatorcontrib><creatorcontrib>Levine, Rachel M.</creatorcontrib><creatorcontrib>Sharma, Akshay</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cytotherapy (Oxford, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bhoopalan, Senthil Velan</au><au>Yen, Jonathan S.</au><au>Levine, Rachel M.</au><au>Sharma, Akshay</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Editing human hematopoietic stem cells: advances and challenges</atitle><jtitle>Cytotherapy (Oxford, England)</jtitle><addtitle>Cytotherapy</addtitle><date>2023-03</date><risdate>2023</risdate><volume>25</volume><issue>3</issue><spage>261</spage><epage>269</epage><pages>261-269</pages><issn>1465-3249</issn><eissn>1477-2566</eissn><abstract>Genome editing of hematopoietic stem and progenitor cells is being developed for the treatment of several inherited disorders of the hematopoietic system. The adaptation of CRISPR-Cas9-based technologies to make precise changes to the genome, and developments in altering the specificity and efficiency, and improving the delivery of nucleases to target cells have led to several breakthroughs. Many clinical trials are ongoing, and several pre-clinical models have been reported that would allow these genetic therapies to one day offer a potential cure to patients with diseases where limited options currently exist. However, there remain several challenges with respect to establishing safety, expanding accessibility and improving the manufacturing processes of these therapeutic products. This review focuses on some of the recent advances in the field of genome editing of hematopoietic stem and progenitor cells and illustrates the ongoing challenges.</abstract><cop>England</cop><pub>Elsevier Inc</pub><pmid>36123234</pmid><doi>10.1016/j.jcyt.2022.08.003</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-9432-9450</orcidid><orcidid>https://orcid.org/0000-0002-3684-2950</orcidid><orcidid>https://orcid.org/0000-0003-3281-2081</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1465-3249 |
| ispartof | Cytotherapy (Oxford, England), 2023-03, Vol.25 (3), p.261-269 |
| issn | 1465-3249 1477-2566 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2716087870 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | CRISPR-Cas Systems - genetics CRISPR-Cas9 Gene Editing - methods Genetic Therapy - methods Hematopoietic Stem Cells Humans severe congenital neutropenia sickle cell disease |
| title | Editing human hematopoietic stem cells: advances and challenges |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T00%3A06%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Editing%20human%20hematopoietic%20stem%20cells:%20advances%20and%20challenges&rft.jtitle=Cytotherapy%20(Oxford,%20England)&rft.au=Bhoopalan,%20Senthil%20Velan&rft.date=2023-03&rft.volume=25&rft.issue=3&rft.spage=261&rft.epage=269&rft.pages=261-269&rft.issn=1465-3249&rft.eissn=1477-2566&rft_id=info:doi/10.1016/j.jcyt.2022.08.003&rft_dat=%3Cproquest_cross%3E2716087870%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2716087870&rft_id=info:pmid/36123234&rft_els_id=S1465324922007496&rfr_iscdi=true |